NIH SBIR/STTR Grants 2026: Phase I $323K, Phase II $2.15M, Receipt Cycles, and the SEED On-Ramp

The National Institutes of Health (NIH) runs one of the largest SBIR programs in the federal government, and for biotechnology, medical-device, diagnostics, and digital-health startups it is the single most important source of non-dilutive capital in the country. It is also the most structurally distinctive: NIH does not use one application or one deadline. It funds through 23 Institutes and Centers (ICs) plus ORIP, on three standing receipt cycles a year, with each Institute weighing scores against its own priorities. SBIR and STTR lapsed on October 1, 2025 and were reauthorized through September 30, 2031 by Public Law 119-83, signed April 13, 2026. The companion STTR program adds a university-partner requirement. This guide names the 2026 dollar guidelines, walks the funding ladder from the SEED on-ramp through Phase IIB, and surfaces the failure modes that sink first-time NIH applications. Before you write a single specific aim, search open NIH SBIR and STTR notices in our Grant Map (agency HHS, keyword "SBIR"). Budgeting a larger NIH research grant? See what the court-blocked 15% indirect-cost cap (the First Circuit affirmed the block on January 5, 2026) means for your F&A rate.

What is the NIH SBIR funding ladder?

The NIH SBIR funding ladder is the sequence of award stages a health startup can climb, from a first-time on-ramp through commercialization support. Unlike a single grant, the ladder lets a company stack non-dilutive capital across years, and understanding the rungs is what separates founders who win one grant from those who build a fundable company on federal money. Each rung has its own eligibility gate.

1. SEED on-ramp + Phase Iup to $323,090

   The entry rung. Phase I funds feasibility research over 6 months to 2 years. Before you apply, Institute programs such as the NIAID Applicant Assistance Program, the NCI Training and Entrepreneurship Program and the NIA Start-Up Challenge help some first-time applicants prepare. Pre-revenue startups routinely enter here.

2. Phase IIup to $2,153,927

   The development rung. Open to Phase I awardees, to companies with equivalent feasibility data through Direct to Phase II, or to Fast-Track applicants submitting both phases at once). Phase II funds full R&D over 1 to 3 years and is scored heavily on commercialization potential.

3. Phase IIB / competing renewalInstitute-set

   The bridge rung. About half of the Institutes accept Phase IIB competing-continuation applications (PA-27-101) to close the gap between Phase II results and market entry; third-party investment counts as evidence of commercial readiness.

4. Commercialization supportNon-grant

   The exit rung. Programs for existing awardees, including I-Corps at NIH (for Phase I awardees), the Needs Assessment report and the Commercialization Readiness Pilot (PAR-27-098, for Phase II and IIB awardees), help awardees reach customers, investors, and regulatory milestones without additional core SBIR cash.

How much is an NIH SBIR grant in 2026?

An NIH SBIR grant in 2026 is governed by SBA statutory guidelines that NIH publishes: $323,090 for Phase Iverified 2026-09-25 and $2,153,927 for Phase IIverified 2026-09-25, per the NIH SEED program guidance. The critical nuance is that these are guidelines, not absolute ceilings. Individual NIH Institutes and Centers can set their own budget limits below the guideline, and NIH holds a waiver from the U.S. Small Business Administration to allow larger awards for specific approved topics. The standing instruction from NIH is explicit: contact the program official before submitting any budget that exceeds the published amounts.

One change matters: NIH no longer relies on paylines. Since the January 2026 council round, Institutes weigh the review score together with their priorities, strategic plans and budget. Institute selection still matters, because each Institute funds its own mission.

2026 application limits: HHS accepts at most 9 Phase I, Fast-Track or Direct-to-Phase II applications per company per fiscal year; each principal investigator may submit at most 6 NIH applications per calendar year; NIH will not consider applications substantially developed by AI (NOT-OD-25-132); and new foreign-risk due diligence under the 2026 reauthorization can lead to award denial (NOT-OD-26-074).

Which NIH Institutes fund the most SBIR?

An NIH Institute or Center is one of the mission-specific funding units within NIH (23 institutes and centers plus ORIP fund small businesses), each with its own research priorities, budget, and SBIR funding considerations. Most applications go through the parent announcements (some Institutes add targeted notices and contract solicitations), so your job is to route your proposal to the Institute whose mission and budget best fit your technology. The matrix below summarizes how the largest small-business funders approach SBIR; consult each Institute's SEED funding-considerations page for current specifics.

When are the NIH SBIR receipt dates?

NIH SBIR and STTR receipt dates are the three standard due-date cycles NIH runs each year for new applications, historically clustered around early September, early January, and early April. The September 5, 2026 date has passed; the next standard receipt dates are January 5, 2027 and April 5, 2027verified 2026-09-25 under PA-27-100 and PA-27-102. The standing cycle is the backbone, but some Institutes layer topic-specific notices of funding opportunity (NOFO) with their own dates, so the rule is to confirm the date in the exact opportunity you apply to. The principal investigator (PI) employment rules also differ between SBIR and STTR, which shapes who can lead the project.

What is the NIH SEED on-ramp?

NIH SEED is the Small Business Education and Entrepreneurial Development office, the part of NIH dedicated to helping small businesses navigate and win SBIR and STTR funding. The SEED website publishes the canonical program guidance, the Institute-by-Institute funding considerations that tell you which Institute funds what, and entrepreneur-support resources. For any founder approaching NIH for the first time, SEED is the correct starting point, ahead of Grants.gov and ahead of any third-party consultant.

SEED also points to support programs. Before you apply, some Institutes run application-assistance programs (the NIAID Applicant Assistance Program, the NCI Training and Entrepreneurship Program, the NIA Start-Up Challenge). After a Phase I award, I-Corps at NIH provides entrepreneurial training with a $25,000 stipend. These are not general cash grants; they are the scaffolding that turns a strong scientific idea into a fundable application, which is exactly where most first-time submissions fall short.

How do you apply for an NIH SBIR grant?

Applying for an NIH SBIR grant is a registration-heavy, Institute-targeted process where the specific aims page does the heavy lifting. Here is the path that works for a first-time applicant.

1. Register in SAM.gov and eRA Commons. Obtain a Unique Entity ID (UEI) in SAM.gov, then register the small business and the principal investigator in eRA Commons. Start 4 to 6 weeks out.
2. Pick the Institute and the opportunity. Use SEED's funding considerations to choose the Institute, then confirm the parent SBIR/STTR notice (PA-27-100 or PA-27-102) or a topic notice is open, and check you are within the 9-per-company and 6-per-PI limits.
3. Email a program officer. Send a short description and ask whether your aims fit the Institute's mission; this five-minute step prevents months of misrouted effort.
4. Write specific aims, then the research strategy. Make every specific aim measurable and tie the proposal to the published review criteria, with a commercialization plan scaled to the phase. Expect study section reviewers to weigh feasibility and significance most heavily.
5. Build a justified budget within the guideline. Keep within $323,090 (Phase I) or $2,153,927 (Phase II) unless the Institute confirms a waiver; justify every line.
6. Submit before the receipt date. Submit via Grants.gov and validate in eRA Commons before the standard receipt date, with buffer for corrections.

Why do NIH SBIR applications get rejected?

NIH study sections see the same avoidable mistakes every cycle. Each is fixable before submission.

NIH-funded biotech founders face a distinctive tax and equity picture: grant income is generally taxable revenue, qualified small business stock treatment can interact with how the company is capitalized, and R&D credits add another layer. Our colleagues at CeoCult cover deductions and grant-income treatment for founders managing federal awards.

Frequently asked questions

Bottom line

NIH is the deepest federal source of non-dilutive capital for health startups, but it rewards founders who treat it as a system rather than a single grant. Climb the ladder deliberately: lean on SEED for your first submission, target the Institute whose mission fits your work, write measurable aims, keep the budget within the $323,090 Phase I and $2,153,927 Phase II guidelines unless a waiver applies, and submit before the January 5, 2027 receipt date. Layer Phase IIB and commercialization support once you are in. For the cross-agency SBIR picture, see our DOE small business grants guide and NSF SBIR Phase II guide, and read each Institute's small-business priorities on NIH SEED. Planning a parent R01, R21, or R15 submission too? The NIH Deadline Calculator tracks those standard due dates with a live countdown.

1. NIH SEED, Understanding SBIR and STTR (2026 Phase I $323,090 and Phase II $2,153,927 guidelines) verified 2026-09-25. NIH SEED, SBIR/STTR funding opportunities (PA-27-100, PA-27-102, PA-27-101, PAR-27-098); NIH Extramural Nexus, "Implementing a Unified NIH Funding Strategy" (November 21, 2025).
2. NIH Office of Extramural Research, SBIR/STTR (program policy, Fast-Track, Phase IIB).
3. NIH eRA Commons (registration and submission system).
4. SBIR.gov (program basics, SBA statutory award guidelines, agency comparison).
5. U.S. Small Business Administration (SBIR/STTR statutory guidelines and waiver authority).